🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

173 results for “inhibitor” Clear

  1. Intrarosa 6.5 mg pessary

    Istituto Gentili S.r.l.

    Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).

    phase 3 small molecule active

    1 trial

  2. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, C1-esterase inhibitor

    Maze Therapeutics

    acute hereditary angioedema attacks

    phase 3 small molecule active

    1 trial

  3. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  4. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  5. MarzAA

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia A With Inhibitor

    phase 3 mab terminated

    1 trial

  6. Monalizumab, Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, CETUXIMAB

    AstraZeneca AB

    Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

    phase 3 small molecule active

    1 trial

  7. Octaplex 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Octaplex 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung

    Lacuna Pharma Pty Ltd

    Acute major bleeding in patients receiving DOAC therapy with factor Xa inhibitor

    phase 3 small molecule active

    1 trial

  8. PCSK9 inhibitors combined with atorvastatin/rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  9. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  10. PRISTINAMYCIN , AMOXICILLIN , CEFTRIAXONE , LEVOFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFOTAXIME PANPHARMA 1 g, poudre pour solution injectable (IM-IV), -

    Pari Pharma GmbH

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  11. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  12. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  13. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  14. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor), VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease (TED)

    phase 3 small molecule active

    1 trial

  15. Sodium Chloride 0.9% Intravenous Infusion, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  16. TOCILIZUMAB, MOXIFLOXACIN, CLARITHROMYCIN, ERYTHROMYCIN LACTOBIONATE, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTRIAXONE, BARICITINIB, HYDROCORTISONE, DEXAMETHASONE, ROXITHROMYCIN, LEVOFLOXACIN, BALOXAVIR MARBOXIL, AZITHROMYCIN, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , AZITHROMYCIN, IMATINIB, OSELTAMIVIR, CLARITHROMYCIN, DEXAMETHASONE, ERYTHROMYCIN

    Disc Medicine

    Respiratory tract infection

    phase 3 small molecule active

    1 trial

  17. Ted sc placebo, VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  18. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  19. Tyrosine kinase inhibitor (TKIs)

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  20. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  21. VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension), TED SC Placebo

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  22. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  23. alpha1-proteinase inhibitor

    Takeda

    Covid19

    phase 3 small molecule terminated

    1 trial

  24. A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources